Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Align Technology (NASDAQ:ALGN) been upgraded to outperform from market perform by Leerink Partners. Calling Align ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Geron in a note issued ...

Align Technology (NASDAQ:ALGN – Get Free Report) was upgraded by investment analysts at Leerink Partnrs from a “hold” rating ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...

(Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of ...

https://www.tipranks.com/news/the-fly/iteos-therapeutics-price-target-lowered-to-19-from-31-at-wells-fargo Leerink analyst Christopher Liu lowered the firm’s price ...

Leerink upgraded Align Technology (ALGN) to Outperform from Market Perform with a price target of $280, up from $235. For what remains a clear ...